Sialadenosis

A non-inflammatory, non-neoplastic bilateral enlargement of the salivary glands, most commonly the parotid glands, reflecting acinar cell hypertrophy secondary to autonomic neuropathy affecting the glandular secretory cells.

It is associated with a range of underlying systemic conditions including diabetes mellitus, alcohol related liver disease, malnutrition, and certain medications. In the context of bulimia nervosa, recurrent vomiting related sialadenosis represents a characteristic, sometimes diagnostically revealing physical sign.

The essential clinical distinction from the more common, generally more concerning causes of salivary gland swelling is the characteristically painless, bilateral, and non-inflammatory nature of this specific condition.

Pathophysiology

• The underlying mechanism is believed to reflect autonomic neuropathy, whether from the direct metabolic effect of diabetes, chronic alcohol toxicity, or nutritional deficiency, affecting the autonomic innervation of the salivary acinar cells, producing secretory granule accumulation and resulting acinar cell hypertrophy, without any associated true inflammatory infiltrate, an important, defining pathophysiological and histological distinction from the various infective and inflammatory salivary gland conditions.

• Bilateral, generally symmetrical, painless, soft to firm parotid gland swelling, developing gradually, represents the characteristic presentation, with the swelling typically non-tender and without associated overlying skin change, fever, or purulent ductal discharge, distinguishing it clinically from acute bacterial sialadenitis or parotitis.
• Relevant underlying associated conditions, including diabetes, chronic alcohol use, an eating disorder with recurrent vomiting (particularly bulimia nervosa, where the associated parotid swelling, termed sialadenosis in this specific context, represents a recognised, characteristic physical examination finding), or significant malnutrition from any cause, should be specifically explored given the direct relevance to identifying the likely underlying cause.

• Diagnosis is predominantly clinical, based on the characteristic bilateral, painless, non-inflammatory swelling pattern together with identification of a relevant underlying associated condition, with ultrasound supporting exclusion of a discrete, focal mass or other structural abnormality that would instead suggest an alternative diagnosis.
• Screening for and confirmation of the specific underlying associated condition (glucose testing, liver function assessment, and, where clinically relevant, specific eating disorder screening) forms an important component of full diagnostic evaluation.

• Management is directed at the underlying associated condition, with optimisation of glycaemic control in diabetes, alcohol cessation support, nutritional rehabilitation where malnutrition or an eating disorder is the underlying cause, and discontinuation of any identified causative medication where clinically feasible, representing the primary management approach, with the gland swelling itself generally not requiring any specific, direct treatment beyond addressing this underlying cause.
• Reassurance regarding the generally benign, non-malignant nature of this condition, together with ongoing management of the identified underlying cause, underpins full management.